Cytokines as Therapeutic Targets to Reduce Cardiovascular Risk in Chronic Inflammation

Author(s): Ashley M. Miller, Iain B. McInnes

Journal Name: Current Pharmaceutical Design

Volume 17 , Issue 1 , 2011

Become EABM
Become Reviewer


Patients with chronic inflammatory diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus, psoriasis and Crohns disease have an increased atherosclerotic risk which cannot be explained by traditional cardiovascular risk factors alone. Inflammatory pathways are implicated in this increased vascular risk. The involvement of cytokine – related signaling pathways in inflammatory diseases has prompted the development of many therapeutic strategies aimed at their modulation to limit disease severity and progression. Whether modulation of these pathways would similarly alter the inflammatory processes related to accelerated atherosclerosis remains unknown. In this review we will focus on the role of pro-inflammatory cytokines and their inhibitors in RA, and whether they may be causal in the accelerated atherosclerosis seen in these patients.

Keywords: Rheumatoid arthritis, cytokine, inflammation, atherosclerosis, anti-microbial and anti-fungicidal properties, L tryptophane, in-dole glucosinolates, alkenyl glucosinolates, bio-fumigants, 2, –, oxazolidimethione, N, hydroxy-amino acid, aldoxime, hydroxy acid, de-sulpho glucosinolate, Moringaceae

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [1 - 8]
Pages: 8
DOI: 10.2174/138161211795049796

Article Metrics

PDF: 20